Stephen L. Eck - Feb 15, 2023 Form 4 Insider Report for MACROGENICS INC (MGNX)

Role
Chief Medical Officer
Signature
/s/ Lynn M. Cilinski, Attorney-in-fact
Stock symbol
MGNX
Transactions as of
Feb 15, 2023
Transactions value $
$0
Form type
4
Date filed
2/17/2023, 03:27 PM
Previous filing
Feb 24, 2022
Next filing
Feb 12, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MGNX Employee stock option (right to buy) Award $0 +200K $0.00 200K Feb 15, 2023 Common Stock 200K $4.82 Direct F1
transaction MGNX Restricted Stock Unit Award $0 +50K $0.00 50K Feb 15, 2023 Common Stock 50K $0.00 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.
F2 Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
F3 The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.